title: Endothelial progenitor cells for vascular regeneration.
abstract: The basis for native as well as therapeutic neovascularization is not restricted to angiogenesis but includes postnatal vasculogenesis. Our laboratory and others' have established that bone marrow-derived endothelial progenitor cells (EPCs) are present in the systemic circulation, are augmented in response to certain cytokines and/or tissue ischemia, and home to as well as incorporate into sites of neovascularization. Given the background, EPCs have been investigated as therapeutic agents in these studies of supply-side angiogenesis under pathological as well as physiological conditions. This review discusses the therapeutic potential of EPCs for cardiovascular ischemic diseases.
authors: Cardiovascular Research and Medicine, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA 02135, USA. asa777@aol.com
authors: Takayuki
authors: T
authors: Asahara
authors: Jeffrey M
authors: JM
authors: Isner
mesh_terms: D000818:Animals; D002318:Cardiovascular Diseases / Q000628:therapy; D004730:Endothelium, Vascular / Q000166:cytology* / Q000502:physiology; D006801:Humans; D018919:Neovascularization, Physiologic; D012038:Regeneration; D033581:Stem Cell Transplantation; D013234:Stem Cells / Q000166:cytology* / Q000502:physiology